Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCI699 randomized withdrawal study in Cushing's disease
2013-004766-34Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of osilodrostat in Corticotropin adenoma (ACTHoma) (3 arms), sponsored by Novartis. Primary endpoint: Complete response rate at Week 34. Started Jun 2014; status: completed.
02
Drugs
osilodrostat
03
Conditions
Corticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on 2013-004766-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004766-34.